Fc gamma riia-specific nucleic acid interference

Title: Fc gamma riia-specific nucleic acid interference

Brief Patent Description - Full Patent Description - Patent Claims

The Patent Description & Claims data below is from USPTO Patent Application 20080293659, Fc gamma riia-specific nucleic acid interference.

1. An RNAi construct for inhibiting the expression of FcγRIIA, comprising (a) an antisense polynucleotide strand that hybridizes to at least a portion of a FcγRIIA transcript and inhibits FcγRIIA expression; and (b) a sense polynucleotide that hybridizes to said antisense polynucleotide.

2. The RNAi construct of claim 1, wherein the double-stranded nucleic acid is a hairpin nucleic acid.

3. The RNAi construct of claim 1, wherein the antisense strand and the sense strand form a double helix of about 19 to about 30 base pairs in length.

4. The RNAi construct of claim 1, wherein the antisense polynucleotide strand is complementary to a sequence of the human FcγRIIA mRNA of SEQ ID NO:1.

5. The RNAi construct of claim 4, wherein the RNA antisense polynucleotide strand is complementary to at least 7 nucleotides of a sequence selected from the group consisting of: SEQ ID Nos. 4-13.

6. The RNAi construct of claim 4, wherein the RNA antisense polynucleotide strand consists of a sequence that is complementary to a sequence selected from the group consisting of: SEQ ID Nos. 4-13.

7. The RNAi construct of claim 4, wherein greater than 50% of the nucleotides of the antisense strand are RNA.

8. The RNAi construct of claim 4, wherein the antisense strand comprises one or more modifications selected from the group consisting of: (a) a modification to the sugar-phosphate backbone; (b) a modification to a base portion of a nucleotide; and (c) a conjugated hydrophobic moiety.

9. The double-stranded nucleic acid of claim 4, wherein the sense strand comprises one or more modifications selected from the group consisting of: (a) a modification to the sugar-phosphate backbone; (b) a modification to a base portion of a nucleotide; and (c) a conjugated hydrophobic moiety.

10. A pharmaceutical preparation for delivery of an RNAi construct to an organism, the composition comprising a pharmaceutically acceptable carrier and an RNAi construct that inhibits expression of FcγRIIA.

11. The pharmaceutical preparation of claim 10, wherein the RNAi construct comprises: (a) an antisense polynucleotide strand that hybridizes to at least a portion of a FcγRIIA transcript and inhibits FcγRIIA expression; and (b) a sense polynucleotide that hybridizes to said antisense polynucleotide.

12. The pharmaceutical preparation of claim 11, wherein the antisense polynucleotide strand is complementary to at least 7 nucleotides of a sequence selected from the group consisting of: SEQ ID Nos. 4-13.

13. The pharmaceutical preparation of claim 11, wherein the antisense polynucleotide strand consists of a sequence that is complementary to a sequence selected from the group consisting of: SEQ ID Nos. 4-13.

14. The pharmaceutical preparation of claim 11, wherein greater than 50% of the nucleotides of the antisense strand are RNA.

15. The pharmaceutical preparation of claim 11, wherein the antisense strand comprises one or more modifications selected from the group consisting of: (a) a modification to the sugar-phosphate backbone; (b) a modification to a base portion of a nucleotide; and (c) a conjugated hydrophobic moiety.

16. The pharmaceutical preparation of claim 11, wherein the sense strand comprises one or more modifications selected from the group consisting of: (a) a modification to the sugar-phosphate backbone; (b) a modification to a base portion of a nucleotide; and (c) a conjugated hydrophobic moiety.

17. The pharmaceutical preparation of claim 10, wherein the preparation is suitable for administration by inhalation.

18. A method for decreasing expression of FcγRIIA in a cell, the method comprising contacting the cell with an RNAi construct which comprises: (a) an antisense polynucleotide strand that hybridizes to at least a portion of a FcγRIIA transcript and inhibits FcγRIIA expression; and (b) a sense polynucleotide that hybridizes to said antisense polynucleotide.

19. The method of claim 18, wherein the antisense polynucleotide strand is complementary to a sequence of the human FcγRIIA mRNA of SEQ ID NO: 1.

20. The method of claim 18, wherein the antisense polynucleotide strand is complementary to at least 7 nucleotides of a sequence selected from the group consisting of: SEQ ID Nos. 4-13.

21. The method of claim 18, wherein the antisense polynucleotide strand consists of a sequence that is complementary to a sequence selected from the group consisting of: SEQ ID Nos. 4-13.

22. A method for decreasing expression of FcγRIIA in one or more cells of an individual, the method comprising administering to the individual a composition comprising an RNAi construct which comprises: (a) an antisense polynucleotide strand that hybridizes to at least a portion of a FcγRIIA transcript and inhibits FcγRIIA expression; and (b) a sense polynucleotide that hybridizes to said antisense polynucleotide.

23. The method of claim 22, wherein the antisense polynucleotide strand is complementary to a sequence of the human FcγRIIA mRNA of SEQ ID NO: 1.

24. The method of claim 22, wherein the antisense polynucleotide strand is complementary to at least 7 nucleotides of a sequence selected from the group consisting of: SEQ ID Nos. 4-13.

25. The method of claim 22, wherein the antisense polynucleotide strand consists of a sequence that is complementary to a sequence selected from the group consisting of: SEQ ID Nos. 4-13.

26. The method of claim 22, wherein the individual has a condition associated with excess Fc receptor activity.

27. The method of claim 22, wherein the individual has asthma or experiences symptoms associated with asthma or allergic rhinitis.

28. The method of claim 27, wherein the composition comprising the RNAi construct is administered by a mode selected from the group consisting of: inhalation, topical and intravenous.

29. The method of claim 22, wherein the individual has an immune cytopenia or a heparin induced thrombocytopenia.

30. The RNAi construct of claim 1, wherein the construct does not substantially inhibit FcγRIIB expression.

Brief Patent Description - Full Patent Description - Patent Claims

Click on the above for other options relating to this Fc gamma riia-specific nucleic acid interference patent application.

Patent Applications in related categories:

20090291906 - Oligomeric compounds and compositions for use in modulation of small non-coding rnas - Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment ...

20090291907 - Oligomeric compounds and compositions for use in modulation of small non-coding rnas - Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment ...

###

How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.
Start now! - Receive info on patent apps like Fc gamma riia-specific nucleic acid interference or other areas of interest.
###

Previous Patent Application:
Combination of ad-p53 and chemotherapy for the treatment of tumours
Next Patent Application:
Method for treating chronic lymphoid leukemia
Industry Class:
Drug, bio-affecting and body treating compositions

###

Design/code © 2009 FreshContext LLC/Freshpatents.com. Website Terms and Conditions - Also read: About this Page
Patent data source: patents published by the United States Patent and Trademark Office (USPTO)
Information published here is for research/educational purposes only (and in conjunction with our Keyword Monitor) and is not meant to be used in place of the full USPTO patent document/images or a comprehensive patent archive search. Complete official applications are on file at the USPTO and often contain additional data/images (Freshpatents is currently text-only). FreshPatents.com is not affiliated with or endorsed by the USPTO or firms/individuals or products/designs/ideas related to listed patents.

FreshPatents.com Support
Thank you for viewing the Fc gamma riia-specific nucleic acid interference patent info.
IP-related news and info

Results in 0.06698 seconds

Other interesting Feshpatents.com categories:
Novartis , Pfizer , Philips , Polaroid , Procter & Gamble , 174

* Protect your Inventions
* US Patent Office filing

Provisional Patent
Utility Patent

PATENT INFO